Theralase Technologies Inc TLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CA$0.18
- Day Range
- CA$0.18–0.19
- 52-Week Range
- CA$0.15–0.41
- Bid/Ask
- CA$0.19 / CA$0.20
- Shares Outstanding
- 310.48M
- Market Cap
- CA$58.99M
- Volume/Avg
- 68,502 / 229,066
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 59.74
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
- Website
- https://www.theralase.com
Valuation
|
Metric
|
TLT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 59.74 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TLT
|
|---|---|
Quick Ratio | 4.89 |
Current Ratio | 5.48 |
Interest Coverage | −63.45 |
Quick Ratio
TLT
Profitability
|
Metric
|
TLT
|
|---|---|
Return on Assets (Normalized) | −78.86% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −117.57% |
Return on Assets
TLT
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|&KXL$p | LOCK|kd%^F | $178B | |||
| Medtronic PLC
MDT
| LOCK|<^>JDm | LOCK|%j&! | $121B | |||
| Stryker Corp
SYK
| LOCK|!HlL%^& | LOCK|jBF | $108B | |||
| Boston Scientific Corp
BSX
| LOCK|?R&&Cx> | LOCK|c>qy | $62B | |||
| Edwards Lifesciences Corp
EW
| LOCK|<Z$xl!s | LOCK|ZKxF% | $50B | |||
| DexCom Inc
DXCM
| LOCK|tlPmw<q | LOCK|Q$ly | $31B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|D?ZC<l | LOCK|@n | $31B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|cx | LOCK|JDx | $25B | |||
| Steris PLC
STE
| LOCK|?%d@?&t | LOCK|?X$g | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|%B$pb^& | LOCK|<$# | $18B |
United States